Charles Schwab’s Alder Biopharmaceuticals ALDR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-426,698
| Closed | -$8.05M | – | 3214 |
|
|
2019
Q3 | $8.05M | Buy |
426,698
+1,476
| +0.3% | +$16.9K | ﹤0.01% | 1725 |
|
|
2019
Q2 | $5M | Buy |
425,222
+43,849
| +11% | +$531K | ﹤0.01% | 1971 |
|
|
2019
Q1 | $5.21M | Buy |
381,373
+56,183
| +17% | +$728K | ﹤0.01% | 1964 |
|
|
2018
Q4 | $3.33M | Sell |
325,190
-2,566
| -0.8% | -$32.9K | ﹤0.01% | 2122 |
|
|
2018
Q3 | $5.46M | Buy |
327,756
+10,674
| +3% | +$193K | ﹤0.01% | 2002 |
|
|
2018
Q2 | $5.01M | Buy |
317,082
+18,415
| +6% | +$280K | ﹤0.01% | 1999 |
|
|
2018
Q1 | $3.79M | Sell |
298,667
-9,583
| -3% | -$139K | ﹤0.01% | 2079 |
|
|
2017
Q4 | $3.53M | Buy |
308,250
+47,816
| +18% | +$534K | ﹤0.01% | 2092 |
|
|
2017
Q3 | $3.19M | Buy |
260,434
+64,988
| +33% | +$678K | ﹤0.01% | 2096 |
|
|
2017
Q2 | $2.24M | Sell |
195,446
-13,827
| -7% | -$256K | ﹤0.01% | 2186 |
|
|
2017
Q1 | $4.35M | Buy |
209,273
+38,123
| +22% | +$844K | ﹤0.01% | 1837 |
|
|
2016
Q4 | $3.56M | Buy |
171,150
+5,160
| +3% | +$134K | ﹤0.01% | 1918 |
|
|
2016
Q3 | $5.44M | Buy |
165,990
+7,932
| +5% | +$242K | 0.01% | 1597 |
|
|
2016
Q2 | $3.95M | Buy |
158,058
+68,610
| +77% | +$1.86M | ﹤0.01% | 1711 |
|
|
2016
Q1 | $2.19M | Buy |
89,448
+1,900
| +2% | +$44K | ﹤0.01% | 2005 |
|
|
2015
Q4 | $2.89M | Buy |
87,548
+15,616
| +22% | +$528K | ﹤0.01% | 1879 |
|
|
2015
Q3 | $2.36M | Buy |
71,932
+42,186
| +142% | +$1.79M | ﹤0.01% | 1973 |
|
|
2015
Q2 | $1.58M | Buy |
29,746
+13,046
| +78% | +$474K | ﹤0.01% | 2208 |
|
|
2015
Q1 | $482K | Buy |
16,700
+5,000
| +43% | +$137K | ﹤0.01% | 2640 |
|
|
2014
Q4 | $341K | Hold |
11,700
| – | – | ﹤0.01% | 2793 |
|
|
2014
Q3 | $149K | Hold |
11,700
| – | – | ﹤0.01% | 3013 |
|
|
2014
Q2 | $235K | Buy |
+11,700
| New | +$165K | ﹤0.01% | 2950 |
|
Charles Schwab's ALDR Position: Q4 2019 in Review
Charles Schwab sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 426,698 shares — an estimated $8.05M sold.
Charles Schwab first reported a position in ALDR in Q2 2014 and held it in 22 quarters. The position peaked at $8.05M in Q3 2019. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.
- Charles Schwab reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
- Charles Schwab sold 426,698 Alder Biopharmaceuticals shares in Q4 2019, an estimated $8.05M.
- Charles Schwab first reported a position in Alder Biopharmaceuticals in Q2 2014 and held it in 22 quarters.
- Charles Schwab's Alder Biopharmaceuticals position peaked at $8.05M in Q3 2019.
- 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.
Based on Charles Schwab's 13F filing for Q4 2019, filed 7 Feb 2020.